Compounds represented by structural formulas described herein, such as Structural Formula (I): or a pharmaceutically acceptable salt thereof are useful in treating conditions such as metal overload, oxidative stress, and neoplastic and preneoplastic conditions.
대표청구항▼
1. A compound represented by Structural Formula (I): wherein: R1 is —H;R2 is —[(CH2)n—O]x—[(CH2)n—O]y—R′;R3, R4, and R5 are each —H;R6 and R7 are each —H;R8 is —H or an alkyl group;R9 is —OR12;R12 is —H or an alkyl group;R′ is an alkyl group;each n is independently an integer from 1 to 8;x is an in
1. A compound represented by Structural Formula (I): wherein: R1 is —H;R2 is —[(CH2)n—O]x—[(CH2)n—O]y—R′;R3, R4, and R5 are each —H;R6 and R7 are each —H;R8 is —H or an alkyl group;R9 is —OR12;R12 is —H or an alkyl group;R′ is an alkyl group;each n is independently an integer from 1 to 8;x is an integer from 1 to 8; andy is an integer from 0 to 8; or a salt thereof. 2. The compound of claim 1, or an alkali metal salt or alkaline earth metal salt thereof, wherein the compound is represented by any one of Structural Formulas (IV) to (IX): 3. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; anda compound of claim 1, or a pharmaceutically acceptable salt thereof. 4. A method of treating a pathological condition in a subject comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the pathological condition is trivalent metal overload, radiation injury, thalassemia, or sickle cell anemia, and wherein the pathological condition is responsive to chelation or sequestration of a trivalent metal. 5. The method of claim 4, wherein R8 is —H or —CH3. 6. The method of claim 5, wherein R2 is —[(CH2)n—O]x—R′; n is an integer from 1 to 4; and x is an integer from 1 to 4. 7. The method of claim 4 comprising administering to the subject a therapeutically effective amount of a compound represented by any one of Structural Formulas (IV) to (IX): or a pharmaceutically acceptable salt thereof. 8. The compound of claim 1, or an alkali metal salt or alkaline earth metal salt thereof. 9. The compound of claim 1, or a sodium salt, potassium salt, magnesium salt, or calcium salt thereof. 10. The compound of claim 1, or a sodium salt thereof. 11. The compound of claim 1, wherein the compound is represented by Structural Formula (V): 12. The salt of claim 1, wherein the salt is an alkali metal salt or alkaline earth metal salt of a compound represented by Structural Formula (V): 13. The salt of claim 1, wherein the salt is a sodium salt, potassium salt, magnesium salt, or calcium salt of a compound represented by Structural Formula (V): 14. The salt of claim 1, wherein the salt is a sodium salt of a compound represented by Structural Formula (V): 15. The method of claim 4, wherein the pathological condition is iron overload. 16. The method of claim 4, wherein the pathological condition is focal iron overload. 17. The method of claim 4, wherein R12 is —H. 18. The method of claim 4, wherein R12 is an alkyl group. 19. The method of claim 4, wherein R12 is C1-4 alkyl. 20. The method of claim 4, comprising administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (V): or a pharmaceutically acceptable salt thereof. 21. The method of claim 4, wherein the pathological condition is global iron overload. 22. The method of claim 4, wherein the pathological condition is dietary iron overload or Bantu siderosis. 23. The method of claim 4, wherein the pathological condition is primary hemochromatosis. 24. The method of claim 4, wherein the pathological condition is secondary hemochromatosis. 25. The method of claim 4, wherein the pathological condition is radiation injury. 26. The method of claim 4, wherein the pathological condition is thalassemia. 27. The method of claim 4, wherein the pathological condition is sickle cell anemia. 28. The method of claim 4, wherein the pathological condition is aluminum overload. 29. The method of claim 4, wherein the pathological condition is chromium overload. 30. The salt of claim 1, wherein the salt is a salt of a compound represented by Structural Formula (V): 31. The salt of claim 1, wherein the salt is a pharmaceutically acceptable salt of a compound represented by Structural Formula (V):
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (72)
Zhner Hans (Tbingen DEX) Naegeli Hans-Ulrich (Muttenz CHX) Peter Heinrich (Binningen CHX), 2-Pyridyl-2-thiazoline-4-carboxylic acid derivatives.
Magnin David R. (Plainsboro NJ) Gordon Eric M. (Pennington NJ), 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same.
Rubin David (4173 Camino Ticino San Diego CA 92122), Anti-tumor compositions containing the reactive product of benzaldehyde or salicylaldehyde with penicillamine and method.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Lewis Terence (Quintilis GB3) Bansal Harjinder S. (Chisbury Close GB3) Sunley Raymond L. (Mallard Close GB3) Kay Ian T. (Mousehole GB3), Herbicidal compositions.
Lewis Terence (Quintilis GB3) Bansal Harjinder S. (Chisbury GB3) Sundley Raymond L. (Mallard GB3) Bartley Michael R. (Lyme Regis GB3) Hepworth Walter (Macclesfield GB3) Gilman David J. (Crowthorne GB, Herbicidal compositions.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Jakob Harald (Hasselroth DEX) Huthmacher Klaus (Gelnhausen DEX) Klenk Herbert (Hanau DEX) Kleemann Axel (Muehlheim DEX) Giray Gunes (Kleinostheim DEX), Optically active salts of a substituted thiazolidine-4-carboxylate and 3-chloro-2-hydroxypropyltrimethyl ammonium, their.
Eicken Karl (Wachenheim DEX) Ditrich Klaus (Bad Duerkheim DEX) Mueller Thomas (Hessheim DEX) Wagner Oliver (Bexbach DEX), Preparation of alkyl 2-alkyl-4-fluoromethylthiazolecarboxylates.
Hamprecht Gerhard (Weinheim DEX) Theobald Hans (Limburgerhof DEX) Spiegler Wolfgang (Worms DEX) Richarz Winfried (Stockstadt DEX) Ammermann Eberhard (Ludwigshafen DEX) Pommer Ernst-Heinrich (Limburge, Quinoline derivatives microbicides containing these compounds, and their use for controlling bacteria and fungi.
Tapper, Amy E.; Rienhoff, Jr., Hugh Y.; Parent, Stephan D.; Andres, Patricia; Hanko, Jason A.; Zhang, Huamin, Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents.
Bru-Magniez Nicole (Paris) Launay Michle (Rueil-Malmaison) Teulon Jean-Marie (La Celle Saint Cloud FRX), Thiazole derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical comp.
Bron Jan (Giessenburg NLX) Sterk Geert J. (Utrecht NLX) Timmerman Hendrik (Voorschooten NLX) Van Der Werf Jan. F. (Amsterdam NLX), Thiazolidine derivatives.
Draeger Eberhard (Frankfurt am Main DEX) Lbbers Henning (Schwalbach DEX), Use of hydroxyphenyl-thiazole-, -thiazoline- and -thiazolidine-carboxylic acids, for influencing the collagen metabolism.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.